

## Anti-IL-17α (Ixekizumab), Humanized Antibody

rev 02/21

CATALOG NO.: A2149-100 (100 µg)

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a humanized IgG4 monoclonal antibody that targets  $IL-17\alpha$  and prevents the interaction with its receptor (IL-17R), thus blocking  $IL-17\alpha$  mediated inflammatory and immune responses.  $IL-17\alpha$  is known to play an important role in autoimmune diseases such as rheumatoid arthritis and plaque psoriasis. The monoclonal antibody is produced in CHO cells using recombinant DNA technology. It consists of two identical light chains of 219 amino acids each and two identical heavy chains of 445 amino acids each. The original monoclonal antibody received approval from the FDA for the treatment of adults suffering from moderate-to-severe psoriasis and psoriatic arthritis.

ALTERNATE NAMES: IL17a, IL17, CTLA8, IL-17, CTLA-8, IL-17A

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

**IMMUNOGEN:** Human IL-17α

**CAS NUMBER:** 1143503-69-8

**PURIFICATION:** Protein A purified


FORM: Liquid


FORMULATION: In PBS, pH 7.5


SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user







SDS-PAGE Analysis to assess purity and integrity of Anti-IL-17α (Ixekizumab), Humanized Antibody

## **RELATED PRODUCTS:**

Anti-IL-4R (Dupilumab), Human IgG4 Antibody (A2148) Anti-IL-12β (Ustekinumab), Human IgG1 Antibody (A2137) Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447) Anti-TNF-α (Adalimumab), humanized Antibody (A1048) Anti-IL-23α (Guselkumab), Human IgG1 Antibody (A2147)

FOR RESEARCH USE ONLY! Not to be used on humans.

